课题基金 / 基金详情

miR-10a regulation of regional arterial endothelial phenotypes in atherosclerosis

miR-10a regulation of regional arterial endothelial phenotypes in atherosclerosis
miR-10a对动脉粥样硬化区域动脉内皮表型的调节
批准号:
8111489
负责人:
Yun Fang
金额:
$8.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-04-01 至 2013-03-31

项目摘要

项目成果

Yun Fang的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):该提案概述了一个综合的研究和职业发展计划,Yun Fang博士将在Peter Davies博士的实验室完成博士后培训,并通过建立心血管病理生理学的多学科研究计划过渡到独立的学术职位。PI目前是美国心脏协会研究员,在分子生物学、生物工程和血管生物学领域接受过培训。在2年的指导期间,PI将从宾夕法尼亚大学的导师和咨询委员会获得额外的学术指导。职业发展计划旨在使PI具备生物医学研究方面的必要知识和技能,以便成功过渡为独立院士,并随着工作的R 00阶段的进展而获得RO 1。总体研究目标是确定microRNA-10a(miR-10a)在介导与动脉粥样硬化发生和发展相关的内皮表型中的作用。微RNA介导的转录后调控在动脉生物学和病理学中知之甚少。K99 PI进行的初步研究表明,不同动脉部位的miR-10a差异地形表达显著促进了与动脉粥样硬化易感性相关的内皮异质性。值得注意的是,在大型动物模型中,在暴露于受干扰血流的动脉粥样硬化易感区域中,内皮miR-10a在体内被显著抑制。进一步的功能基因组学和生物化学分析表明,miR-10 a通过抑制NF-B介导的炎症促进内皮细胞中的动脉粥样硬化保护表型(PNAS出版中)。该研究提案测试了总体假设,即流动和/或高胆固醇血症敏感的miR-10a动态调节动脉粥样硬化起始和进展中的内皮表型。目的1将检验动脉粥样硬化保护性miR-10a通过直接抑制一组阳性NF-B和未折叠蛋白应答(UPR)应答分子来抑制内皮炎症和内质网应激(ER应激)的假设。目的2将检验以下假设:动脉粥样硬化相关的血液动力学力调节机械敏感性转录因子,导致体内动脉粥样硬化易感区域和动脉粥样硬化保护区域的内皮miR-10a生物合成的差异控制。目的3将建立一种内皮miR-10a可诱导表达的转基因小鼠模型,以证明内皮miR-10a表达与动脉粥样硬化的因果关系,从而在体内验证动脉粥样硬化保护性miR-10a抑制内皮炎症和ER应激,减轻动脉粥样硬化负担的假设。这一目标将通过在体外和体内系统中整合系统生物学和分子分析来实现,从而对内皮miR-10a的下游基因网络和上游调节因子与动脉粥样硬化的机制进行理解。 公共卫生相关性:动脉粥样硬化导致大多数心血管疾病,如心脏病发作和中风。斑块在易受疾病影响的动脉的可预测部位发展。这些部位有不寻常的血流,这会影响动脉内皮细胞,使它们容易发生病变。我的研究分析了称为microRNA的小核酸在细胞中与动脉粥样硬化易感性和血流相关的调节作用。我们希望确定microRNA相关的靶点,用于心血管疾病的治疗干预。
英文摘要
DESCRIPTION (provided by applicant): The proposal outlines an integrated research and career development plan for Yun Fang, Ph.D to complete postdoctoral training in the laboratory of Dr. Peter Davies and transition to an independent academic position by establishing a multi-disciplinary research program in cardiovascular pathophysiology. The PI is currently an American Heart Association Fellow who is trained in the fields of molecular biology, bioengineering, and vascular biology. During the 2 year mentored period, the PI will receive additional academic guidance from the mentor and the advisory committee at the University of Pennsylvania. The career development plan is designed to equip the PI with necessary knowledge and skills in biomedical research for a successful transition as an independent academician, leading to a RO1 as the R00 phase of the work progresses. The overall research goal is to determine the role of microRNA-10a (miR-10a) in mediating endothelial phenotypes in relation to the initiation and development of atherosclerosis. MicroRNA-mediated post-transcriptional regulation is poorly understood in arterial biology and pathology. Preliminary studies conducted by the K99 PI demonstrate that differential topographic expression of miR-10a in distinct arterial sites significantly contributes to the endothelial heterogeneity associated with susceptibility to atherosclerosis. Notably, endothelial miR-10a is significantly suppressed in vivo in athero-susceptible regions exposed to disturbed blood flow in a large animal model. Further functional genomics and biochemical analyses demonstrated that miR-10a promotes the athero-protective phenotype in endothelial cells by suppressing NF-B-mediated inflammation (PNAS in press). The research proposal tests the overall hypothesis that flow and/or hypercholesterolemia-sensitive miR-10a dynamically modulates endothelial phenotypes in the initiation and progression of atherosclerosis. Aim 1 will test the hypothesis that athero-protective miR-10a suppresses endothelial inflammation and Endoplasmic Reticulum stress (ER stress) by direct inhibition of a cohort of positive NF-B and Unfolded Protein Response (UPR) responsive molecules. Aim 2 will test the hypothesis that athero- relevant hemodynamic force regulates mechano-sensitive transcription factors, leading to differential control of endothelial miR-10a biogenesis at athero-susceptible and athero-protected regions in vivo. And Aim 3 will develop a transgenic mouse model that exhibits inducible expression of endothelial miR-10a to demonstrate the causality of endothelial miR-10a expression and atherosclerosis, thereby testing in vivo the hypothesis that athero-protective miR-10a inhibits endothelial inflammation and ER stress, alleviating atherosclerotic burden. The goal will be achieved by integrating system biology and molecular analysis in both in vitro and in vivo systems, leading to mechanistic understandings of the down-stream gene networks and up-stream regulators of endothelial miR-10a with respect to atherosclerosis. PUBLIC HEALTH RELEVANCE: Atherosclerosis causes most cardiovascular diseases such as heart attack and stroke. The plaques develop in predictable sites of arteries which are susceptible to disease. The sites have unusual blood flow which affects the endothelial cells lining the artery and predisposes them to lesions. My studies analyze the regulatory role of small nucleic acids called microRNAs in cells in relation to atherosusceptibility and blood flow. We hope to define microRNA-related targets for therapeutic intervention in cardiovascular disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Precision nanomedicine targeting novel endothelial mechano-sensing mechanisms
  • 批准号:
    10630052
  • 项目类别:
  • 资助金额:
    $81.1万
  • 财政年份:
    2022
  • 负责人:
    Yun Fang
  • 依托单位:
Precision nanomedicine targeting novel endothelial mechano-sensing mechanisms
  • 批准号:
    10354607
  • 项目类别:
  • 资助金额:
    $80.52万
  • 财政年份:
    2022
  • 负责人:
    Yun Fang
  • 依托单位:
Coronary artery disease locus 1p32.2 and miR92a-PPAP2B signaling in endothelial mechanobiology
  • 批准号:
    10171493
  • 项目类别:
  • 资助金额:
    $39.9万
  • 财政年份:
    2017
  • 负责人:
    Yun Fang
  • 依托单位:
Spatial Delivery of MicroRNA Inhibitor via Targeted Polyelectrolyte Complex Micelles to Treat Atherosclerosis.
  • 批准号:
    10229491
  • 项目类别:
  • 资助金额:
    $39.48万
  • 财政年份:
    2017
  • 负责人:
    Yun Fang
  • 依托单位:
海外基金